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background
 
Epigenetic silencing of the 
 
MGMT
 
 (O
 
6
 
-methylguanine–DNA methyltransferase) DNA-
repair gene by promoter methylation compromises DNA repair and has been associated
with longer survival in patients with glioblastoma who receive alkylating agents.
 
methods
 
We tested the relationship between 
 
MGMT
 
 silencing in the tumor and the survival of
patients who were enrolled in a randomized trial comparing radiotherapy alone with
radiotherapy combined with concomitant and adjuvant treatment with temozolomide.
The methylation status of the 
 
MGMT
 
 promoter was determined by methylation-specific
polymerase-chain-reaction analysis.
 
results
 
The 
 
MGMT
 
 promoter was methylated in 45 percent of 206 assessable cases. Irrespective
of treatment, 
 
MGMT
 
 promoter methylation was an independent favorable prognostic
factor (P<0.001 by the log-rank test; hazard ratio, 0.45; 95 percent confidence interval,
0.32 to 0.61). Among patients whose tumor contained a methylated 
 
MGMT
 
 promoter,
a survival benefit was observed in patients treated with temozolomide and radiotherapy;
their median survival was 21.7 months (95 percent confidence interval, 17.4 to 30.4),
as compared with 15.3 months (95 percent confidence interval, 13.0 to 20.9) among
those who were assigned to only radiotherapy (P=0.007 by the log-rank test). In the ab-
sence of methylation of the 
 
MGMT
 
 promoter, there was a smaller and statistically insig-
nificant difference in survival between the treatment groups.
 
conclusions
 
Patients with glioblastoma containing a methylated 
 
MGMT
 
 promoter benefited from
temozolomide, whereas those who did not have a methylated 
 
MGMT
 
 promoter did not
have such a benefit.
abstract
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pigenetic silencing of the 
 
mgmt
 
(O
 
6
 
-methylguanine–DNA methyltransfer-
ase) gene by promoter methylation has been
associated with longer overall survival in patients
with glioblastoma who, in addition to radiotherapy,
received alkylating chemotherapy with carmustine
or temozolomide.
 
1,2
 
 The 
 
MGMT
 
 gene is located on
chromosome 10q26 and encodes a DNA-repair pro-
tein that removes alkyl groups from the O
 
6
 
 position
of guanine, an important site of DNA alkylation.
The restoration of the DNA consumes the MGMT
protein, which the cell must replenish. Left unre-
paired, chemotherapy-induced lesions, especially
O
 
6
 
-methylguanine, trigger cytotoxicity and apopto-
sis.
 
3,4
 
 High levels of MGMT activity in cancer cells
create a resistant phenotype by blunting the thera-
peutic effect of alkylating agents and may be an im-
portant determinant of treatment failure.
 
5-10
 
 Epi-
genetic silencing of the 
 
MGMT
 
 gene by promoter
methylation is associated with loss of MGMT ex-
pression
 
11-13
 
 and diminished DNA-repair activity.
In the course of tumor development, gene silencing
by DNA methylation is an early and important
mechanism by which tumor-suppressor genes are
inactivated.
 
14,15
 
In a phase 2 evaluation of combined radiotherapy
and temozolomide for newly diagnosed glioblas-
toma, we found that methylation of the 
 
MGMT
 
promoter in the tumor was associated with longer
survival.
 
2
 
 In the current study, we investigated
whether 
 
MGMT
 
 promoter methylation in glioblas-
toma is associated with a benefit from temozolo-
mide treatment. We determined the 
 
MGMT
 
 pro-
moter methylation status in tumor tissues from
patients who were enrolled in a randomized trial
that showed a survival advantage among patients
treated with temozolomide and radiotherapy as
compared with radiotherapy alone.
 
16
 
patients and treatment
 
Patients were enrolled in a randomized trial of
chemoradiotherapy (temozolomide plus radiother-
apy) versus radiotherapy alone (carried out by the
European Organisation for Research and Treatment
of Cancer and the National Cancer Institute of Can-
ada [NCIC]) (EORTC trial 26981/22981 and NCIC
trial CE.3).
 
16
 
 Patients in the experimental group re-
ceived the alkylating agent temozolomide (Temodal
or Temodar, Schering-Plough) at a dose of 75 mg
per square meter of body-surface area daily during
standard fractionated radiotherapy (60 Gy) for 6 to
7 weeks and at a dose of 150 to 200 mg per square
meter per day for 5 days of every 28-day cycle after
radiotherapy, for up to six cycles. In the case of
tumor progression, salvage or second-line therapy
was administered at the investigators’ discretion;
most patients received additional chemotherapy. All
patients provided written informed consent for mo-
lecular studies of their tumor, and the protocol was
approved by the ethics committee at each center.
 
dna extraction and methylation-specific 
polymerase chain reaction
 
Genomic DNA was isolated from one or two paraf-
fin sections of glioblastoma tissue (Ex-Wax DNA
Extraction Kit S4530, Chemicon) (proteinase diges-
tion lasted a maximum of six hours). DNA was de-
natured with sodium hydroxide in a volume of 35 µl
and subjected to bisulfite treatment in a volume of
360 µl (4.4 M sodium bisulfite and 20 mM hydro-
quinone) for five hours at 55°C and then purified
(Wizard DNA Clean-Up System A7280, Promega).
Unmethylated cytosine, but not its methylated coun-
terpart, is modified into uracil by the treatment.
The methylation-specific polymerase chain reaction
(PCR) was performed in a two-step approach.
 
17
 
The results were confirmed in an independent ex-
periment, starting with reisolation of DNA from the
tumor. The PCR products were separated on 4 per-
cent agarose gels. The investigators who selected
and analyzed the glioblastoma samples were blind-
ed to all clinical information.
 
statistical analysis
 
Overall and progression-free survival curves were
estimated by the Kaplan–Meier technique and
compared with use of the two-sided log-rank test.
All treatment comparisons are presented on an
intention-to-treat basis according to the random-
ized assignment. The Cox proportional-hazards
model was fitted to assess the prognostic and pre-
dictive values of the methylation status of the
 
MGMT
 
 promoter, the protocol treatment, and po-
tential prognostic factors
 
18
 
 that were found to be
statistically significant in this population on the
basis of univariate testing.
 
organization of the study
 
This project was initiated and carried out without
the involvement of a commercial sponsor. Dr. Hegi
designed and supervised the translational study
and wrote the manuscript, with input from the co-
authors. Methylation-specific PCR was performed
by Ms. Diserens. The statistical analysis was per-
e
methods
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formed by Mr. Gorlia. The clinical trial was designed
and directed by Dr. Stupp, in collaboration with the
EORTC and the NCIC Clinical Trials Group.
Methylation-specific PCR was performed on 307 of
573 glioblastoma specimens (53.6 percent) from
patients enrolled at 66 of 85 participating centers
(Fig. 1); adequate paraffin-embedded tumor tissue
was not available from 266 patients. 
 
MGMT
 
 meth-
ylation status could be determined for 206 of the
307 tumors (67.1 percent), or 36.0 percent of the
tumors from the overall study population. The suc-
cess rate of methylation-specific PCR on paraffin-
embedded tumor samples was highly variable and
center-dependent. For centers with four or more
testable samples, the median success rate was 75.0
percent (range, 0 to 100 percent). Treatment as-
signments among the 307 patients with evaluable
tumor specimens was equally distributed, with 152
patients (49.5 percent) randomly assigned to radio-
therapy alone and 155 (50.5 percent) randomly as-
signed to temozolomide and radiotherapy.
The subgroup of 206 patients in whom 
 
MGMT
 
promoter methylation status could be determined
was representative of the overall treatment popula-
tion with respect to known prognostic factors and
outcomes. However, the proportion of patients who
had only a diagnostic biopsy specimen (and no de-
bulking surgery) was smaller in the subgroup test-
ed for 
 
MGMT
 
 promoter methylation than in the sub-
group of patients in whom methylation status could
not be determined (3.4 percent vs. 23.0 percent).
Overall survival did not vary significantly according
to whether or not the test was attempted (P=0.27
by the log-rank test) or whether or not the results
were interpretable (P=0.23 by the log-rank test)
(Fig. 1 of the Supplementary Appendix, available
with the full text of this article at www.nejm.org).
Of the 206 evaluated tumors, 92 (44.7 percent) had
detectable 
 
MGMT
 
 promoter methylation, whereas
114 (55.3 percent) did not. The proportion of
methylated tumors was similar in the two treat-
ment groups (Table 1).
For the entire population of 206 patients for
whom 
 
MGMT
 
 status could be evaluated, there was
a significant difference, irrespective of treatment
assignment, in overall survival between patients
whose tumors had 
 
MGMT
 
 promoter methylation
and those whose tumors did not (P<0.001 by the
log-rank test) (Fig. 2). The hazard ratio for death
was 0.45 (95 percent confidence interval, 0.32 to
results
 
Figure 1. Methylation Status of the 
 
MGMT
 
 Promoter in Glioblastoma Biopsy 
Specimens, as Determined by a Nested Methylation-Specific PCR Assay.
 
DNA from normal peripheral blood lymphocytes (PBL) was used as a control 
for the unmethylated 
 
MGMT
 
 promoter (U), enzymatically methylated DNA 
from PBL (MPBL) served as a positive control for the methylated 
 
MGMT
 
 pro-
moter (M), and water was used as a negative control for the PCR. A 100-bp 
marker ladder was loaded to estimate molecular size, as shown on the left 
scale; the sizes of PCR products are indicated on the right scale. Glioblastoma 
numbers 549 and 527 contain a methylated promoter, whereas 555, 569, and 
529 harbor only an unmethylated promoter. The nested PCR approach ren-
ders the analysis highly sensitive, while allowing it to retain the specificity that 
results in the detection of unmethylated 
 
MGMT
 
 promoter in all specimens 
that may also contain DNA derived from infiltrating lymphocytes, blood ves-
sels, or contaminating normal tissue.
300 bp —
200 bp —
100 bp — — 93 bp
— 81 bp
U M U M U M U M U M U M U MU M
549 555 569
M
ar
ke
r
Water 527 529 MPBL PBL
 
* Numbers in parentheses are 95 percent confidence intervals.
 
† None of the patients in this subgroup were followed up for two years.
 
Table 1. Effect of 
 
MGMT
 
 Promoter Methylation Status on Survival, 
According to Random Treatment Assignment.*
Promoter Status and Outcome
Radiotherapy
(N=100)
Temozolomide plus
Radiotherapy (N=106)
Methylated 
 
MGMT
 
 promoter
 
No. of patients 46 46
Progression-free survival
Median duration (mo) 5.9 (5.3–7.7) 10.3 (6.5–14.0)
Rate at 6 mo (%) 47.8 (33.4–62.3) 68.9 (55.4–82.4)
Hazard ratio for death 1.00 0.48 (0.31–0.75)
Overall survival
Median duration (mo) 15.3 (13.0–20.9) 21.7 (17.4–30.4)
Rate at 2 yr (%) 22.7 (10.3–35.1) 46.0 (31.2–60.8)
Hazard ratio for death 1.00 0.51 (0.31–0.84)
 
Unmethylated 
 
MGMT
 
 promoter
 
No. of patients 54 60
Progression-free survival
Median duration (mo) 4.4 (3.1–6.0) 5.3 (5.0–7.6)
Rate at 6 mo (%) 35.2 (22.5–47.9) 40.0 (27.6–52.4)
Hazard ratio for death 1.00 0.62 (0.42–0.92)
Overall survival
Median duration (mo) 11.8 (9.7–14.1) 12.7 (11.6–14.4)
Rate at 2 yr (%) <2† 13.8 (4.8–22.7)
Hazard ratio for death 1.00 0.69 (0.47–1.02)
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0.61) among those with 
 
MGMT
 
 promoter methyl-
ation, a result that corresponds to a 55 percent de-
crease in the risk of death in this subgroup. The
median overall survival among patients with meth-
ylation was 18.2 months (95 percent confidence in-
terval, 15.5 to 22.0), as compared with 12.2 months
(95 percent confidence interval, 11.4 to 13.5) among
those without methylation.
When both treatment assignment and 
 
MGMT
 
promoter methylation status were considered, the
longest median overall survival, 21.7 months, was
observed among patients with promoter methyla-
tion who were assigned to receive both temozolo-
mide and radiotherapy (Table 1). Their two-year
survival rate was 46.0 percent, as compared with
22.7 percent among those with 
 
MGMT
 
 promoter
methylation who were assigned to radiotherapy
alone. Kaplan–Meier estimates of overall survival
in these two subgroups were significantly different
(P=0.007 by the log-rank test) (Fig. 3A). 
By contrast, among patients whose tumors were
not methylated at the 
 
MGMT
 
 promoter, the differ-
ence in overall survival favoring the temozolomide-
plus-radiotherapy group was only marginally sig-
nificant (P=0.06 by the log-rank test) (Fig. 3A); the
median survival was 12.7 months among those
assigned to temozolomide and radiotherapy and
11.8 months among those assigned to radiotherapy,
with 2-year survival rates of 13.8 percent and less
than 2 percent, respectively (Table 1). The interac-
tion between the magnitude of the treatment effect
and 
 
MGMT
 
 promoter methylation status with re-
spect to overall survival was not statistically signif-
icant, according to the Cox proportional-hazards
model (P=0.29) (Table 2). However, this result was
not unexpected, since neither the clinical trial nor
this study was powered to test the interaction.
In addition, a probable confounding factor in
the analysis of overall survival was the administra-
tion of temozolomide or other alkylating chemo-
therapy as salvage or second-line treatment after
disease progression. More than 70 percent of the
patients in the radiotherapy group received sal-
vage chemotherapy; 59.7 percent received temozo-
lomide. In the temozolomide-plus-radiotherapy
group, 57.8 percent received second-line chemo-
therapy; 24.6 percent were retreated with temozo-
lomide. We therefore analyzed progression-free sur-
vival relative to 
 
MGMT
 
 promoter methylation status
and treatment assignment (Fig. 3B and Table 1).
In the group of patients whose tumors con-
tained a methylated 
 
MGMT
 
 promoter, those who re-
ceived temozolomide and radiotherapy had a me-
dian progression-free survival of 10.3 months, as
compared with 5.9 months for patients who re-
ceived radiotherapy alone (P=0.001). Among the
patients whose tumors contained an unmethylated
 
MGMT 
 
promoter, those who received temozolomide
and radiotherapy had a median progression-free
survival of 5.3 months, as compared with 4.4
months for patients who were treated with radio-
therapy alone (P=0.02) (Fig. 3B). The relatively long
overall survival despite the short progression-free
survival among patients with a methylated 
 
MGMT
 
promoter who were assigned to receive only radio-
therapy indicates that salvage therapy at the time of
recurrence has some efficacy in this subpopulation.
To analyze further the influence of the methyla-
tion status of the 
 
MGMT
 
 promoter, we performed a
multivariate analysis with the use of the Cox pro-
portional-hazards model, stratified according to
treatment group and including known clinical prog-
nostic factors (Table 2). The methylation status of
the 
 
MGMT
 
 promoter (P<0.001) and the score on the
 
Figure 2. Kaplan–Meier Estimates of Overall Survival, According to 
 
MGMT
 
 
Promoter Methylation Status.
 
The difference in survival between patients with a methylated 
 
MGMT
 
 pro-
moter (92 patients, 65 of whom died) and those with an unmethylated 
 
MGMT
 
 
promoter (114 patients, 105 of whom died) was highly significant (P<0.001 by 
the log-rank test), indicating that the 
 
MGMT
 
 methylation status has prognos-
tic value. In the group of patients with a methylated 
 
MGMT
 
 promoter, there 
was a risk reduction of 55 percent (hazard ratio for death, 0.45; 95 percent 
confidence interval, 0.32 to 0.61), as compared with the group with an un-
methylated 
 
MGMT
 
 promoter.
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Figure 3. Kaplan–Meier Estimates of Overall and Progression-free Survival, According to 
 
MGMT
 
 Promoter Methylation 
Status and Random Assignment to Temozolomide plus Radiotherapy or Radiotherapy Alone.
 
The Kaplan–Meier estimates for overall survival indicate that the group of patients with a methylated 
 
MGMT
 
 promoter 
who were randomly assigned to temozolomide and radiotherapy (46 patients, 40 of whom had progression and 27 of 
whom died) had a 49 percent risk reduction (hazard ratio for death, 0.51; 95 percent confidence interval, 0.31 to 0.84), 
as compared with the group with a methylated 
 
MGMT
 
 promoter who were randomly assigned to radiotherapy only (46 
patients, 45 of whom had progression and 38 of whom died) (Panel A). An unmethylated 
 
MGMT
 
 promoter and random 
assignment to temozolomide and radiotherapy (60 patients, 53 of whom had progression and 52 of whom died) yielded 
a risk reduction of 31 percent (hazard ratio for death, 0.69; 95 percent confidence interval, 0.47 to 1.02), as compared 
with an unmethylated 
 
MGMT
 
 promoter and random assignment to radiotherapy only (54 patients, all of whom had pro-
gression and 53 of whom died). In order to display a possible effect of salvage treatment on overall survival, in particular 
in the group of patients with a methylated 
 
MGMT
 
 promoter who were randomly assigned to radiotherapy alone. Kaplan–
Meier curves are also shown for progression-free survival (Panel B) in a similar manner.
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Mini–Mental State Examination (P=0.007) emerged
as significant independent prognostic factors. The
adjusted hazard ratio of 0.41 (95 percent confidence
interval, 0.29 to 0.57) for 
 
MGMT
 
 promoter meth-
ylation was consistent with the unadjusted hazard
ratio of 0.45 (95 percent confidence interval, 0.32
to 0.61).
We found that 
 
MGMT
 
 promoter methylation is as-
sociated with a favorable outcome after temozolo-
mide chemotherapy in patients with newly diag-
nosed glioblastoma. Our data suggest that the
methylation status of the 
 
MGMT
 
 promoter may have
prognostic value and, in addition, may be a clini-
cally relevant predictor of benefit from temozolo-
mide chemotherapy. Despite the survival benefit as-
sociated with temozolomide among patients with
a methylated 
 
MGMT
 
 promoter, the overall survival
curves for temozolomide and radiotherapy and for
radiotherapy alone remain similar for the first nine
months of follow-up. This suggests that 
 
MGMT
 
methylation, though important, is not the sole fac-
tor determining outcome. Lack of mismatch-repair
has also been shown to render tumors resistant to
alkylating agents, even in the absence of MGMT.
 
4
 
Additional mechanisms and predictive factors are
likely to be relevant and need to be identified.
Diagnostic 
 
MGMT
 
 testing requires sufficient
and optimally preserved tumor tissue. The best re-
sults with methylation-specific PCR are obtained
with cryopreserved tumor specimens, thus avoid-
ing fixation-related deterioration of the quality of
tumor DNA. Other methods, such as immunohis-
tochemistry or activity testing, may not be reliable,
since MGMT expression is prone to induction by
glucocorticoids, ionizing radiation, and genotoxic
agents
 
19,20
 
 when the 
 
MGMT
 
 promoter is not meth-
ylated.
Determination of MGMT promoter methylation
status by methylation-specific PCR may allow the
selection of patients most likely to benefit from
temozolomide treatment; patients whose tumors
are not methylated at the 
 
MGMT
 
 promoter appear
to derive little or no benefit from the addition of
temozolomide to radiotherapy. For these patients,
alternative treatments with a different mechanism
of action or methods of inhibiting MGMT should
be developed.
 
21,22 
 
Our findings may be applicable
to other solid tumors commonly treated with alkyl-
ating agents, such as melanoma, but possibly also
to lung and breast cancer and lymphoma. Stratifi-
cation according to 
 
MGMT
 
 promoter methylation
status may be considered in future trials in which
temozolomide or other alkylating agents are used.
 
Supported by grants from the Swiss Institute of Applied Cancer
Research, the Nélia and Amadeo Barletta Foundation, and the EORTC
Translational Research Fund 2002 (to Drs. Hegi and Stupp); by
Award 2002 from the Jacqueline Seroussi Memorial Foundation
for Cancer Research (to Dr. Hegi); by a grant (3100-64050.00/1, to
Dr. Hegi) from the Swiss National Science Foundation; and by a
grant (1123/1124-2-2001, to Dr. Hegi) from OncoSuisse.
Drs. Hegi, Mason, Mariani, Cairncross, Mirimanoff, and Stupp
report having received consulting and lecture fees from Schering-
Plough. Drs. Hegi and Stupp report having received consulting fees
from OncoMethylome Sciences, and Dr. Stupp (consulting fees
from EMD Pharmaceuticals).
We are indebted to all the patients and their families for having
agreed to participate in this trial and to donate tumor biopsy speci-
mens for translational research; to Solange Gros for technical assis-
tance; to Denis Lacombe, Anouk Allgeier, and Linda de Prijck (of the
EORTC Data Center) and Elizabeth Eisenhauer and Marina Djur-
field (of the NCIC Clinical Trials Group office); and to all investiga-
tors at the clinical centers who participated in the trial and who
made the paraffin-embedded material available for this translation-
al research effort.
discussion
 
* CI denotes confidence interval, and NA not applicable.
 
Table 2. Results of Analyses with the Cox Proportional-Hazards Models.* 
Variable Prognostic-Factor Model Predictive-Factor Model
 
P Value
Hazard Ratio
(95% CI) P Value
Hazard Ratio
(95% CI)
 
MGMT
 
 promoter methylation and temozolomide plus 
radiotherapy (vs. no methylation or radiotherapy)
NA NA 0.29 0.71 (0.37–1.35)
Temozolomide plus radiotherapy (vs. radiotherapy) NA NA 0.06 0.68 (0.45–1.02)
 
MGMT
 
 promoter methylation (vs. no methylation) <0.001 0.41 (0.29–0.57) 0.001 0.49 (0.32–0.76)
Age (continuous) 0.47 1.01 (0.99–1.02) 0.36 1.01 (0.99–1.03)
Mini–Mental State Examination score (continuous 
increments)
0.007 0.94 (0.89–0.98) 0.004 0.93 (0.89–0.98)
Use of corticosteroids at randomization (vs. nonuse) 0.07 1.41 (0.97–2.04) 0.08 1.39 (0.96–2.00)
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clinical trial registration
The Journal encourages investigators to register their clinical trials in a public trials 
registry. The members of the International Committee of Medical Journal Editors 
plan to consider clinical trials for publication only if they have been registered 
(see N Engl J Med 2004;351:1250-1). The National Library of Medicine’s 
www.clinicaltrials.gov is a free registry, open to all investigators, that meets 
the committee’s requirements.
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